Does P Gp Or Bcrp Substrates Interact with Imlunestrant?
CDI records a major classification for P Gp Or Bcrp Substrates and Imlunestrant. The stored summary is: Imlunestrant inhibits P-gp and BCRP, increasing substrate exposure and risk of adverse reactions. Avoid concomitant use unless minimal concentration changes are acceptable. The mechanism involves imlunestrant inhibits p-gp and bcrp transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Imlunestrant Class
- Estrogen Receptor Antagonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Imlunestrant inhibits P-gp and BCRP transporters
What To Tell Your Doctor or Pharmacist
If you are taking P Gp Or Bcrp Substrates and your doctor is considering prescribing Imlunestrant (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider